Please assess the completion status of the following clinical trial:

Trial Title: Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed type 1 diabetes within 1 week of diagnosis~* Age 6 - 18 years~* Care provided at Children's Medical Center, Dallas~Exclusion Criteria:~* Actual treatment with oral drugs influencing beta cell function or blood glucose levels (e.g. oral hypoglycemic agents)~* Actual treatment with drugs influencing insulin sensitivity (e.g. Metformin, or systemic steroids)~* Significant concomitant disease likely to interfere with glucose metabolism (children with active bacterial infections at the time of diagnosis must be cured prior to entry)~* Expected poor compliance~* Pregnancy~* Any other condition that by the judgement of the investigator may be potentially harmful to the patients

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Detemir (Type: EXPERIMENTAL): 24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
- Glargine (Type: EXPERIMENTAL): 24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
- NPH (Type: EXPERIMENTAL): 24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).